Gabapentin and Mood/Anxiety Changes in Children
Gabapentin carries significant risk for behavioral and mood changes in children, particularly those aged 3-12 years, and should not be used for anxiety disorders in pediatric patients. The FDA-approved drug label explicitly warns that gabapentin use in children 3-12 years can cause emotional changes, aggressive behavior, problems with concentration, restlessness, and hyperactivity 1.
Key Behavioral Risks in Children
The FDA drug label provides the most authoritative guidance: Gabapentin causes neuropsychiatric adverse reactions in pediatric patients, classified into four categories 1:
- Emotional lability (primarily behavioral problems): 6% vs 1.3% placebo
- Hostility (including aggressive behaviors): 5.2% vs 1.3% placebo
- Thought disorder (concentration problems, changes in school performance): 1.7% vs 0% placebo
- Hyperkinesia (restlessness and hyperactivity): 4.7% vs 2.9% placebo
These reactions led to treatment discontinuation in 1.3% for emotional lability/hyperkinesia and 0.9% for hostility/thought disorder 1.
Clinical Evidence from Research
Multiple pediatric studies confirm these behavioral concerns. Children with baseline ADHD and developmental delays appear particularly vulnerable—all seven children in one case series who developed behavioral side effects had pre-existing ADHD 2. The behavioral changes included:
- Intensification of baseline behaviors
- New behavioral problems (tantrums, aggression, defiance)
- Explosive outbursts with oppositional behavior
- Severe enough to require discontinuation despite improved seizure control 2, 3
Critical caveat: All behavioral changes were reversible with dose reduction or discontinuation 2.
Lack of Efficacy for Anxiety in Children
For anxiety disorders specifically, gabapentin has no role. The 2020 AACAP anxiety guideline establishes that SSRIs and cognitive-behavioral therapy are the evidence-based treatments for pediatric anxiety 4. Gabapentin is not mentioned as a treatment option for anxiety in children.
Furthermore, controlled studies in adults found gabapentin not helpful for mood disorders 5, and there is no evidence supporting its use for anxiety in pediatric populations.
Suicidal Ideation Risk
Gabapentin carries an FDA boxed warning for suicidal thoughts and behavior in all ages. The pooled risk across antiepileptic drugs shows 4.3 per 1000 drug-treated patients vs 2.4 per 1000 placebo patients developed suicidal thoughts/behavior 1. This represents approximately one additional case for every 530 patients treated, with risk emerging as early as one week after starting treatment.
Monitoring Requirements
When gabapentin must be used in children (for FDA-approved indications like epilepsy), implement this monitoring protocol:
Immediate monitoring (first month):
- Weekly assessment for behavioral changes, particularly aggression, hyperactivity, emotional lability
- Screen for suicidal thoughts at every contact
- Monitor school performance and concentration
Ongoing monitoring:
- Assess for mood changes, irritability, restlessness at each visit
- Educate parents/caregivers to report behavioral concerns immediately
- Consider dose reduction if behavioral symptoms emerge before discontinuation
High-risk populations requiring extra vigilance:
- Children with pre-existing ADHD or developmental delays 2
- Children under 12 years old (highest risk group) 1
- Those with baseline behavioral problems
Management of Behavioral Side Effects
If behavioral changes occur:
- Do not abruptly discontinue - risk of precipitating seizures in epilepsy patients 1
- Gradual taper while monitoring for symptom resolution
- All behavioral effects are reversible with dose reduction or discontinuation 2
- Consider alternative agents appropriate for the underlying condition
Bottom Line
Gabapentin should not be prescribed for anxiety or mood symptoms in children. When used for FDA-approved indications (epilepsy, neuropathic pain), prescribers must counsel families about the substantial risk of behavioral activation, aggression, and mood changes, particularly in children 3-12 years with ADHD or developmental delays. Close monitoring for these effects and suicidal ideation is mandatory, with readiness to taper if behavioral symptoms emerge.